Trial Design

How independent endpoint assessment committees can overcome imaging limitations.

Reductions in unused data will improve study performance, lower costs, and address ethical concerns.

Hear Dr. Robertson speak about the need to collaborate on discoveries for diabetes treatments in order to improve future global health.

Changing current business models with the use of new advancements for more sustainability.

Success and challenges for clinical trials that address these interrelated conditions.

Patient-level feedback from later studies provides a multitude of valuable answers to all stakeholders.

A concise look at this nontraditional approach to clinical studies that explains the how and why of it.

Understanding and using adaptive trial design to achieve the most of its available advantages.

Uses for next generation information management, called health intelligence, in research.

Using tumor xenograft technology in drug targets and personalized medicine.

Making adaptations to clinical trials in the early stages of research with the use of interim data.

The spirited decades-old journey of interferon alfa.

A look at the different testing methods and how the results impact drug development.

Developing and utilizing a comprehensive feasibility strategy to avoid risk and ensure the most efficient clinical trial.

Panel members discuss "Working Together to Develop Biomarkers for Safety Monitoring and Surrogate Endpoints," at IIR's Central Labs Partnering conference.

Industry professionals address the changes taking place in pharma and propose an upheaval of current business models to welcome new ones that are adapted for the ever-evolving clinical trials climate.

Realizing the need for flexible technology when implementing EDC in late-phase research.

A clinical trials professional with personal experience as a trial subject discusses the purpose and importance of following protocol.

Surveys among pharma, clinics, and investigators shed light on trials in children.

Finding new ways to design and conduct clinical trials in order to prevent Phase III failures.

Acceptance of data ambiguity by the industry is the key to adaptive design adoption and use.

With help from technology, adaptive trials can enhance dose selection and reduce time between phases.